TrialInvestigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
Trial details
- Registry ID
- NCT03562832
- Phase
- Phase 2
ALLR
Allarity Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRPNCT03562832 | Allarity Therapeutics | Phase 2 | Completed | 2024-04-01Actual |
| Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)NCT03643107 | Allarity Therapeutics | Phase 2 | Completed | 2021-10-01Actual |
| Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerNCT03878849 | Allarity Therapeutics | Phase 2 | Recruiting | 2027-03Estimated |
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.NCT04796324 | Allarity Therapeutics | Phase 2 | Terminated | 2024-12-01Actual |
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Trial details
- Registry ID
- NCT03643107
- Phase
- Phase 2
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Trial details
- Registry ID
- NCT03878849
- Phase
- Phase 2
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Trial details
- Registry ID
- NCT04796324
- Phase
- Phase 2
Latest recorded trial changes
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
NCT04796324 · Allarity Therapeutics
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 60; type: ESTIMATED
+ Updated value
count: 13; type: ACTUAL
Recruitment status
Recorded edit− Previous value
Suspended
+ Updated value
Terminated